X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1282) 1282
Publication (83) 83
Conference Proceeding (17) 17
Newsletter (8) 8
Book Review (7) 7
Book / eBook (5) 5
Book Chapter (4) 4
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (566) 566
oncology (566) 566
female (517) 517
breast cancer (363) 363
breast neoplasms - drug therapy (327) 327
index medicus (300) 300
middle aged (256) 256
breast neoplasms - pathology (212) 212
adult (207) 207
aged (204) 204
chemotherapy (188) 188
cancer (147) 147
antineoplastic combined chemotherapy protocols - therapeutic use (145) 145
prognosis (143) 143
treatment outcome (136) 136
antineoplastic agents - therapeutic use (128) 128
trastuzumab (125) 125
chemotherapy, adjuvant (120) 120
breast neoplasms - genetics (112) 112
therapy (106) 106
disease-free survival (105) 105
hematology, oncology and palliative medicine (105) 105
breast neoplasms - mortality (86) 86
breast neoplasms - metabolism (79) 79
care and treatment (79) 79
research (75) 75
adjuvant chemotherapy (73) 73
receptor, erbb-2 - metabolism (69) 69
clinical trials (68) 68
survival (68) 68
neoplasm staging (66) 66
tumors (66) 66
drug administration schedule (64) 64
breast neoplasms - therapy (63) 63
drug therapy (59) 59
docetaxel (58) 58
male (58) 58
postmenopausal women (58) 58
randomized controlled trials as topic (58) 58
medicine & public health (57) 57
metastasis (57) 57
tamoxifen (57) 57
gene expression (54) 54
paclitaxel (53) 53
survival analysis (52) 52
neoplasm metastasis (51) 51
expression (48) 48
follow-up studies (48) 48
doxorubicin (47) 47
clinical trials as topic (46) 46
trial (46) 46
antibodies, monoclonal, humanized (45) 45
antineoplastic combined chemotherapy protocols - adverse effects (45) 45
antineoplastic agents - administration & dosage (44) 44
aged, 80 and over (43) 43
lapatinib (43) 43
women (43) 43
antineoplastic agents, hormonal - therapeutic use (42) 42
carcinoma (42) 42
endocrine therapy (42) 42
health aspects (42) 42
surgery (42) 42
analysis (41) 41
dose-response relationship, drug (41) 41
gene expression profiling (41) 41
open-label (41) 41
paclitaxel - administration & dosage (41) 41
tamoxifen - therapeutic use (41) 41
breast neoplasms - chemistry (40) 40
her2 (40) 40
randomized-trial (40) 40
medicine, general & internal (39) 39
receptors, estrogen - metabolism (39) 39
risk factors (39) 39
adjuvant treatment (38) 38
biomarkers, tumor - analysis (38) 38
receptor, erbb-2 - analysis (38) 38
cancer therapies (37) 37
cyclophosphamide - administration & dosage (37) 37
estrogen (37) 37
ovarian neoplasms - drug therapy (37) 37
antineoplastic agents - adverse effects (36) 36
neoplasms - drug therapy (36) 36
patients (36) 36
receptor, erbb-2 - genetics (36) 36
antibodies, monoclonal - therapeutic use (35) 35
immunohistochemistry (35) 35
survival rate (35) 35
efficacy (34) 34
genetic aspects (34) 34
pharmacology & pharmacy (34) 34
prospective studies (34) 34
quality of life (34) 34
lymphatic metastasis (33) 33
medical research (33) 33
predictive value of tests (33) 33
breast neoplasms - diagnosis (32) 32
breast neoplasms - surgery (32) 32
cyclophosphamide (32) 32
europe (32) 32
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9897, pp. 1021 - 1028
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1137 - 1146
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9793, pp. 771 - 784
Journal Article